Quest PharmaTech Inc. (CVE:QPT – Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as C$0.04 and last traded at C$0.04, with a volume of 688986 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Price Performance
The firm’s 50 day moving average price is C$0.03 and its two-hundred day moving average price is C$0.03. The firm has a market capitalization of C$5.07 million, a PE ratio of -1.50 and a beta of 0.14. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Further Reading
- Five stocks we like better than Quest PharmaTech
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Comparing and Trading High PE Ratio Stocks
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
